Intelligent Bio Solutions Inc. (INBS)vsJohnson & Johnson (JNJ)
INBS
Intelligent Bio Solutions Inc.
$1.76
-3.83%
HEALTHCARE · Cap: $5.27M
JNJ
Johnson & Johnson
$273.25
-0.73%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2356490% more annual revenue ($99.33B vs $4.22M). JNJ leads profitability with a 16.2% profit margin vs -294.9%. JNJ earns a higher WallStSmart Score of 57/100 (C).
INBS
Avoid31
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.9%
Fair Value
$4.27
Current Price
$1.76
$2.51 premium
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$273.25
$129.13 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 35.8% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -170.2% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 35.8% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
INBS profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.30 — expect wider price swings.
INBS is growing revenue faster at 35.8% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 31/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a pioneering biotechnology company focused on delivering cutting-edge diagnostic solutions and biomarker-driven technologies, specifically designed for drug abuse testing and monitoring. Utilizing advanced scientific methodologies, INBS offers rapid and precise testing options that enhance clinical decision-making processes and improve patient outcomes. In a healthcare landscape increasingly reliant on innovative diagnostic tools, INBS is well-positioned to make substantial contributions to this evolving field, reinforcing its dedication to advancing healthcare quality and operational effectiveness.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?